Development of A MERS-CoV Replicon Cell Line for Antiviral Screening.

Szczegóły
Abstrakt

Tytuł:: Development of A MERS-CoV Replicon Cell Line for Antiviral Screening.
Autorzy:: Chen J; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Hu BJ; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Zhao K; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Luo Y; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Lin HF; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Shi ZL; CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China. .
Źródło:: Virologica Sinica [Virol Sin] 2021 Aug; Vol. 36 (4), pp. 730-735. Date of Electronic Publication: 2021 Feb 22.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2022- : [Amsterdam, Netherlands] : Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
Original Publication: Beijing : Science Press
MeSH Terms:: Antiviral Agents*/pharmacology
Cell Line*
Drug Evaluation, Preclinical*
Middle East Respiratory Syndrome Coronavirus*/genetics
Coronavirus Infections/drug therapy ; Humans ; Lopinavir/therapeutic use ; Replicon
References:: Almazan F, Galan C, Enjuanes L (2004) The nucleoprotein is required for efficient coronavirus genome replication. J Virol 78:12683–12688. (PMID: 10.1128/JVI.78.22.12683-12688.2004)
Almazan F, DeDiego ML, Galan C, Escors D, Alvarez E, Ortego J, Sola I, Zuniga S, Alonso S, Moreno JL, Nogales A, Capiscol C, Enjuanes L (2006) Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol 80:10900–10906. (PMID: 10.1128/JVI.00385-06)
Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, The Mtg (2018) Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19:81. (PMID: 10.1186/s13063-017-2427-0)
Arabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jeraisy M, Mandourah Y, Azzam MHA, Bin Eshaq AM, Al Johani S, Al Harbi S, Jokhdar HAA, Deeb AM, Memish ZA, Jose J, Ghazal S, Al Faraj S, Al Mekhlafi GA, Sherbeeni NM, Elzein FE, Al-Hameed F, Al Saedi A, Alharbi NK, Fowler RA, Hayden FG, Al-Dawood A, Abdelzaher M, Bajhmom W, AlMutairi BM, Hussein MA, Alothman A (2020) Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. N Engl J Med 383:1645–1656. (PMID: 10.1056/NEJMoa2015294)
Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA (2014) Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370:2499–2505. (PMID: 10.1056/NEJMoa1401505)
Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H (2018) Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology 514:134–141. (PMID: 10.1016/j.virol.2017.11.003)
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. (PMID: 10.1038/nrmicro.2016.81)
Dudas G, Carvalho LM, Rambaut A, Bedford T (2018) MERS-CoV spillover at the camel-human interface. Elife 7:e31257.
Ge F, Xiong S, Lin FS, Zhang ZP, Zhang XE (2008) High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery. Antiviral Res 80:107–113. (PMID: 10.1016/j.antiviral.2008.05.005)
Hertzig T, Scandella E, Schelle B, Ziebuhr J, Siddell SG, Ludewig B, Thiel V (2004) Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 85:1717–1725. (PMID: 10.1099/vir.0.80044-0)
Hurst KR, Koetzner CA, Masters PS (2013) Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex. J Virol 87:9159–9172. (PMID: 10.1128/JVI.01275-13)
Kato F, Nio Y, Yagasaki K, Suzuki R, Hijikata M, Miura T, Miyazaki I, Tajima S, Lim CK, Saijo M, Takasaki T, Hishiki T (2019) Identification of inhibitors of dengue viral replication using replicon cells expressing secretory luciferase. Antiviral Res 172:104643. (PMID: 10.1016/j.antiviral.2019.104643)
Kuo L, Hurst-Hess KR, Koetzner CA, Masters PS (2016) Analyses of Coronavirus Assembly Interactions with Interspecies Membrane and Nucleocapsid Protein Chimeras. J Virol 90:4357–4368. (PMID: 10.1128/JVI.03212-15)
Lee JY, Bae S, Myoung J (2019) Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design. J Microbiol 57:803–811. (PMID: 10.1007/s12275-019-9272-7)
Muller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, Sieberg A, Aldabbagh S, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Albarrak AM, Al-Shangiti AM, Al-Tawfiq JA, Wikramaratna P, Alrabeeah AA, Drosten C, Memish ZA (2015) Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infectious Diseases 15:559–564. (PMID: 10.1016/S1473-3099(15)70090-3)
Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM, Altmeyer R, Peiris JS, Bruzzone R, Nal B (2008) The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol 82:11318–11330. (PMID: 10.1128/JVI.01052-08)
van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3:e00473–e00512. (PMID: 231700023509437)
WHO (2019) Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/.
Xie X, Zou J, Shan C, Yang Y, Kum DB, Dallmeier K, Neyts J, Shi PY (2016) Zika Virus Replicons for Drug Discovery. EBioMedicine 12:156–160. (PMID: 10.1016/j.ebiom.2016.09.013)
Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, Zhao Z, Tan W (2013) The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4:951–961. (PMID: 10.1007/s13238-013-3096-8)
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820. (PMID: 10.1056/NEJMoa1211721)
Zeng LP, Gao YT, Ge XY, Zhang Q, Peng C, Yang XL, Tan B, Chen J, Chmura AA, Daszak P, Shi ZL (2016) Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response. J Virol 90:6573–6582. (PMID: 10.1128/JVI.03079-15)
Zhang Y, Song W, Chen S, Yuan Z, Yi Z (2021) A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. Antiviral Res 185:104974. (PMID: 10.1016/j.antiviral.2020.104974)
Zúñiga S, Cruz JL, Sola I, Mateos-Gómez PA, Palacio L, Enjuanes L (2010) Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol 84:2169–2175. (PMID: 10.1128/JVI.02011-09)
Contributed Indexing:: Keywords: Antiviral screening; Luciferase reporter gene; Middle East respiratory syndrome coronavirus (MERS-CoV); Replicon cell line
Substance Nomenclature:: 0 (Antiviral Agents)
2494G1JF75 (Lopinavir)
Entry Date(s):: Date Created: 20210222 Date Completed: 20210927 Latest Revision: 20210927
Update Code:: 20240105
PubMed Central ID:: PMC7898024
DOI:: 10.1007/s12250-020-00341-z
PMID:: 33616893
: Czasopismo naukowe

Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the Renilla luciferase (Rluc) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.
(© 2021. Wuhan Institute of Virology, CAS.)

Informacja